<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996005</url>
  </required_header>
  <id_info>
    <org_study_id>7429</org_study_id>
    <nct_id>NCT03996005</nct_id>
  </id_info>
  <brief_title>MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer</brief_title>
  <acronym>MRI-TULSAP</acronym>
  <official_title>Evaluation of an Alternative Treatment of Localized Prostate Cancer by Guided MRI Transurtral Ultrasound With 1-year Control of the Absence of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose :&#xD;
&#xD;
      Evaluation of the efficiency and safety of an alternative global prostate treatment in&#xD;
      localized prostate cancer.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      Absence of clinically significant cancer (CSC) on control biopsy at 1-year follow-up.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. Biochemical response&#xD;
&#xD;
        2. Presence of any CSC on biopsy at 1- and 2-year follow-up&#xD;
&#xD;
        3. Radical treatment free survival&#xD;
&#xD;
        4. Adverse events, clinical tolerance&#xD;
&#xD;
        5. Urinary continence&#xD;
&#xD;
        6. Erectile function&#xD;
&#xD;
        7. Quality of life&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of clinically significant cancer (CSC) on control biopsy at 1-year follow-up.</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically significant cancer (CSC) defined by at least one of the following criteria:&#xD;
Gleason score ≥ 7&#xD;
cancer core length &gt; 3 mm regardless of Gleason score&#xD;
&gt; 2 positive cores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>Month 3</time_frame>
    <description>PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>Month 6</time_frame>
    <description>PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>Month 12</time_frame>
    <description>PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of any CSC on biopsy at 1-year follow-up</measure>
    <time_frame>at 1-year follow-up</time_frame>
    <description>Pathology analysis of the biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radical treatment free survival</measure>
    <time_frame>at 1-year follow-up</time_frame>
    <description>Evaluation of the complication according to Dindo-Clavien</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, clinical tolerance</measure>
    <time_frame>at 1-year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary continence</measure>
    <time_frame>Month 3</time_frame>
    <description>Urinary continence evaluation by using the USP scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary continence</measure>
    <time_frame>Month 6</time_frame>
    <description>Urinary continence evaluation by using the USP scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary continence</measure>
    <time_frame>Month 12</time_frame>
    <description>Urinary continence evaluation by using the USP scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile function</measure>
    <time_frame>Month 3</time_frame>
    <description>Erectile function evaluated by using the IIEF15 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile function</measure>
    <time_frame>Month 6</time_frame>
    <description>Erectile function evaluated by using the IIEF15 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile function</measure>
    <time_frame>Month 12</time_frame>
    <description>Erectile function evaluated by using the IIEF15 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EORTC QLQ-C30 scale.</measure>
    <time_frame>Month 3</time_frame>
    <description>EORTC QLQ-C30 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EORTC QLQ-C30 scale.</measure>
    <time_frame>Month 6</time_frame>
    <description>EORTC QLQ-C30 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EORTC QLQ-C30 scale.</measure>
    <time_frame>Month 12</time_frame>
    <description>EORTC QLQ-C30 scale.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>MRI Guided Transurethral Ultrasound Ablation</condition>
  <condition>Localized Prostate Cancer</condition>
  <condition>Ablation Therapy</condition>
  <arm_group>
    <arm_group_label>MRI Guided Transurethral Ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue</intervention_name>
    <description>Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue</description>
    <arm_group_label>MRI Guided Transurethral Ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patient ≥ 50 years old&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Gleason ≤ 7 (3 + 4) ; Grade group ≤ 2 according to Epstein&#xD;
&#xD;
          -  Clinically &lt;T3, N0, M0&#xD;
&#xD;
          -  PSA &lt; 15 ng/mL&#xD;
&#xD;
          -  Prostate volume &lt;100g&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Life expectancy higher than 12 months in the judgement of the investigator&#xD;
&#xD;
          -  Radiological TNM (prostate MRI) T ≤ 2 (absence of extra-capsular extension, absence of&#xD;
             seminal vesicle invasion), N = 0, M = 0&#xD;
&#xD;
          -  First line of treatment or relapse after initial radiotherapy&#xD;
&#xD;
          -  Willing to give signed, informed consent freely&#xD;
&#xD;
          -  Able to adhere to the follow-up schedule and other protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Contraindication to general anesthesia&#xD;
&#xD;
          -  Presence or history of any other malignancy except for non-melanoma skin cancer&#xD;
             adequately treated at least 2 years before study entry&#xD;
&#xD;
          -  Unreversible haemostasis disorder&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibault TRICARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

